Search

Highlights from the article: Our analysis did conclude a gain of 1.3 quality-adjusted life-years (QALYs) for VN compared with SoC as stated by Buessing et al., and they conclude that this implies an 8% improvement in the patient's quality of life. Nevertheless, we did complete a scenario analysis around this assumption, available in the publicly available ICER report, which resulted in higher health gains and lower costs for VN patients relative to the base-case scenario. Future studies of long-term health outcomes, quality of life, and indirect costs for patients with RPE65-mediated inherited retinal disease would improve our understanding of the economic and health impacts of new treatments.